Germany Oncology Based In-vivo Cro Market Size & Outlook
Germany oncology based in-vivo cro market, 2018-2030 (US$M)
Related Markets
Germany oncology based in-vivo cro market highlights
- The Germany oncology based in-vivo cro market generated a revenue of USD 148.0 million in 2023 and is expected to reach USD 260.4 million by 2030.
- The Germany market is expected to grow at a CAGR of 8.4% from 2024 to 2030.
- In terms of segment, solid tumor was the largest revenue generating indication in 2023.
- Solid Tumor is the most lucrative indication segment registering the fastest growth during the forecast period.
Oncology based in-vivo cro market data book summary
| Market revenue in 2023 | USD 148.0 million |
| Market revenue in 2030 | USD 260.4 million |
| Growth rate | 8.4% (CAGR from 2023 to 2030) |
| Largest segment | Solid tumor |
| Fastest growing segment | Solid Tumor |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Solid Tumor |
| Key market players worldwide | Charles River Laboratories International Inc, Icon PLC, Thermo Fisher Scientific Inc, Eurofins Scientific SE, Labcorp Holdings Inc, Wuxi AppTec Co Ltd, Evotec SE, Taconic Biosciences, The Jackson Laboratory |
Other key industry trends
- In terms of revenue, Germany accounted for 11.1% of the global oncology based in-vivo cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany oncology based in-vivo cro market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 172.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oncology Based In-vivo CRO Market Scope
Oncology Based In-vivo CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Germany oncology based in-vivo cro market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology based in-vivo cro market will help companies and investors design strategic landscapes.
Solid tumor was the largest segment with a revenue share of 47.16% in 2023. Horizon Databook has segmented the Germany oncology based in-vivo cro market based on blood cancer, solid tumor covering the revenue growth of each sub-segment from 2018 to 2030.
In terms of the market size, Germany has the largest outsourcing market with major expansions of the companies in other European countries. In July 2014, Accovion, a full-service CRO, expanded in other European countries such as France, Italy, and Eastern Europe.
German CROs are of interest for international companies, hence, there are many acquisitions, which is accelerating the CRO industry in the country. In March 2013, SynteractHCR, a U.S. based multinational CRO, acquired Harrison Clinical Research with an aim of positioning itself as a top-tier CRO provider. Evotec, a CRO, has more than 70 alliances with mid-sized and large pharma companies.
The company has increased its R&D spending to attract more clients with USD 13.1 million spent in 2014 and is expected to spend around USD 21.8 million by 2015. The demand for CROs is increasing and the company also receives contracts from the UK, France, and the U.S. In March 2015, Sanofi signed a strategic partnership for five years with Evotec to innovate new drugs and candidates in oncology.
Reasons to subscribe to Germany oncology based in-vivo cro market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Germany oncology based in-vivo cro market databook
-
Our clientele includes a mix of oncology based in-vivo cro market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany oncology based in-vivo cro market , including forecasts for subscribers. This country databook contains high-level insights into Germany oncology based in-vivo cro market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Germany oncology based in-vivo cro market size, by indication, 2018-2030 (US$M)
Germany Oncology Based In-vivo CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
